Qualitative and quantitative characterization of Fas (APO-1/CD95) on leukemic cells derived from patients with B-cell neoplasms

Leukemia Research

Volumn 23, Issue 2, 1999, Pages 159-166

  Tsuruda, Kazuto ^a   Yamada, Yasuaki ^a   Hirakata, Yoichi ^a   Sugahara, Kazuyuki ^a   Maeda, Takahiro ^a   Atogami, Sunao ^a   Tomonaga, Masao ^a   Kamihira, Shimeru ^a  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; B cell neoplasm; Fas (APO 1 CD95); Flow cytometry

Indexed keywords

FAS ANTIGEN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; B CELL LYMPHOMA; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FLOW CYTOMETRY; HAIRY CELL LEUKEMIA; HUMAN; HUMAN CELL; LEUKEMIA CELL; MULTIPLE MYELOMA; PRIORITY JOURNAL;

ANTIGENS, CD95; APOPTOSIS; FLOW CYTOMETRY; HUMANS; LEUKEMIA, B-CELL, ACUTE; LEUKEMIA, B-CELL, CHRONIC; LEUKEMIA, HAIRY CELL; LYMPHOMA, B-CELL; MULTIPLE MYELOMA; RNA, MESSENGER;

EID: 0032903514     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(98)00158-1     Document Type: Article

References (26)

1. Yonehara S., Ishii A., Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigens co-downregulated with the receptor of tumor necrosis factor. J. Exp. Med. 169:1989;1747-1756.
2. Itoh N., Yonehara S., Ishii A., Yonehara M., Mizushima S., Saimeshima M. et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell. 66:1991;233-243.
3. Suda T., Takahashi T., Golstein P., Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 75:1993;1169-1178.
4. Oehm A., Behrmann I., Falk W., Pawlita M., Maier G., Klas C. et al. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J. Biol. Chem. 267:1992;10709-10715.
5. Debatin K.M., Suss D., Krammer P.H. Differential expression of APO-1 on human thymocytes: implications for negative selection? Eur. J. Immunol. 24:1994;753-758.
6. Krammer P.H., Behrmann I., Daniel P., Dhein J., Debatin K.M. Regulation of apoptosis in the immune system. Curr. Opin. Immunol. 6:1994;279-289.
7. Sugahara K., Yamada Y., Hiragata Y., Matsuo Y., Tsuruda K., Tomonaga M. et al. Soluble and membrane isoforms of Fas/CD95 in fresh adult T-cell leukemia (ATL) cells and ATL-cell lines. Int. J. Cancer. 72:1997;1-5.
8. Kamihira S., Yamada Y., Hirakata Y., Sugahara K., Tomonaga M., Maeda T. et al. Quantitative characterization and potential function of membrane Fas/APO-1 (CD95) receptors on leukemic cells from chronic B and T lymphoid leukemias. Br. J. Haematol. 99:1997;858-865.
9. Selleri C., Sato T., Vecchio L.D., Luciano L., Barrett A.J., Rotoli B. et al. Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia. Blood. 89:1997;957-964.
10. Iijima N., Miyamura K., Itou T., Tanimoto M., Sobue R., Saito H. Functional expression of Fas (CD95) in Acute myeloleukemia cells in the context of CD34 and CD 38 expression: Possible correlation with sensitivity to chemotherapy. Blood. 90:1997;4901-4909.
11. Panayiotidis P., Ganeshaguru K., Foroni L., Hoffbrand A.V. Expression and function of the FAS antigen in B chronic lymphocytic leukemia and hairy cell leukemia. Leukemia. 9:1995;1227-1232.
12. Galle P.R., Hofmann W.J., Walczak H., Schaller H., Otto G., Stremmel W. et al. Development of the CD95(APO-1/Fas) receptor and ligand in liver damage. J. Exp. Med. 182:1995;1223-1230.
13. von Reyher U., Strater J., Kittstein W., Gschwendt M., Krammer H., Maller P. Colon Carcinoma cells use different mechanism to escape CD95-mediated apoptosis. Cancer Res. 58:1998;526-534.
14. Daniel P.T., Krammer P.H. Activation induces sensitivity toward APO-1 (CD95)-mediated apoptosis in human B cells. J. Immunol. 152:1994;5624-5632.
15. Bennet J.M., Catovsky D., Daniel M.T. et al. Proposals for the classification of acute leukemias. French-American-British (FAB) Cooperative group. Br. J. Haematol. 33:1976;451-458.
16. Bennet J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A.G., Gralnick H.R. et al. Proposals for the classification of chronic (mature) B and T lymphoid leukemias. J. Clin. Pathol. 42:1989;567-584.
17. Kamihira S., Sohda H., Atogami S., Toriya Y., Yamada K., Tsukasaki S. et al. Phenotypic diversity and prognosis of adult T-cell leukemia. Leukemia Res. 16:1992;435-441.
18. Poncelet P., Carayon P. Cytofluorometric quantification of cell surface antigen by indirect immunofluorescence using monoclonal antibodies. J. Immunol. Methods. 85:1985;65-745.
19. Vermes I., Haanen C., Steffens-Nakken H., Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J. Immunol. Methods. 184:1995;39-51.
20. Koopman G., Reutelingsperger C.P.M., Kuijten G.A.M., Keehnen R.M.J., Pals S.T., Van Oers M.H.J. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood. 84:1995;1415-1420.
21. Cheng J., Zhout T., Liu C., Shapiro J.P., Brauer M. J., Kiefer M.C. et al. Protetion from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science. 263:1994;1759-1762.
22. Landowski T.H., Qu N., Buyuksal I., Painter J. S., Dalton W.S. Mutations in the Fas antigen in patients with multiple myeloma. Blood. 99:1997;4266-4270.
23. Fulda S., Los M., Friesen C., Debatin K.M. Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system. Int. J. Cancer. 76:1998;105-114.
24. Plumas J., Jacob M.J., Chaperot L., Molens J.P., Sotto J., Bensa J.C. Tumor B cells from non-Hodgkin's lymphoma are resistant to CD95(Fas/Apo-)-mediated apoptosis. Blood. 91:1998;2875-2885.
25. Baiocchi R.A., Khatri V.P., Lindemann M. J., Ross M.E., Papoff G., Caprio A.J. et al. Phenotypic and functional analysis of Fas(CD95) expression in primary central nervous system lymphoma of patients with acquired immunodeficiency syndrome. Blood. 90:1997;1737-1746.
26. Maciejewski J., Selleri C., Anderson S., Young N. S. Fas antigen expression on CD34+ human marrow cells is induced by interferon-γ and tumor necrosis factor-alpha potentiates cytokine-mediated hematopoietic suppression in vitro. Blood. 85:1995;3183-3190.